journal
MENU ▼
Read by QxMD icon Read
search

Blood Cancer Journal

journal
https://www.readbyqxmd.com/read/30190469/long-term-efficacy-and-safety-of-dasatinib-in-patients-with-chronic-myeloid-leukemia-in-accelerated-phase-who-are-resistant-to-or-intolerant-of-imatinib
#1
LETTER
Oliver Ottmann, Giuseppe Saglio, Jane F Apperley, Christopher Arthur, Eduardo Bullorsky, Aude Charbonnier, John F Dipersio, Hagop Kantarjian, Hanna Jean Khoury, Dong-Wook Kim, Diane Healey, Lewis Strauss, Jorge E Cortes
No abstract text is available yet for this article.
September 3, 2018: Blood Cancer Journal
https://www.readbyqxmd.com/read/30190467/gata2-zinc-finger-1-mutations-are-associated-with-distinct-clinico-biological-features-and-outcomes-different-from-gata2-zinc-finger-2-mutations-in-adult-acute-myeloid-leukemia
#2
Feng-Ming Tien, Hsin-An Hou, Cheng-Hong Tsai, Jih-Luh Tang, Yu-Chiao Chiu, Chien-Yuan Chen, Yuan-Yeh Kuo, Mei-Hsuan Tseng, Yen-Ling Peng, Ming-Chih Liu, Chia-Wen Liu, Xiu-Wen Liao, Liang-In Lin, Chien-Ting Lin, Shang-Ju Wu, Bor-Sheng Ko, Szu-Chun Hsu, Shang-Yi Huang, Ming Yao, Wen-Chien Chou, Hwei-Fang Tien
Mutations of the GATA binding protein 2 (GATA2) gene in myeloid malignancies usually cluster in the zinc finger 1 (ZF1) and the ZF2 domains. Mutations in different locations of GATA2 may have distinct impact on clinico-biological features and outcomes in AML patients, but little is known in this aspect. In this study, we explored GATA2 mutations in 693 de novo non-M3 AML patients and identified 44 GATA2 mutations in 43 (6.2%) patients, including 31 in ZF1, 10 in ZF2, and three outside the two domains. Different from GATA2 ZF2 mutations, ZF1 mutations were closely associated with French-American-British (FAB) M1 subtype, CEBPA double mutations (CEBPAdouble-mut ), but inversely correlated with FAB M4 subtype, NPM1 mutations, and FLT3-ITD...
August 31, 2018: Blood Cancer Journal
https://www.readbyqxmd.com/read/30190454/lenalidomide-and-dexamethasone-in-patients-with-relapsed-multiple-myeloma-and-impaired-renal-function-pre1003-a-precog-study
#3
Joseph Mikhael, Judith Manola, Amylou C Dueck, Suzanne Hayman, Kurt Oettel, Abraham S Kanate, Sagar Lonial, S Vincent Rajkumar
Renal insufficiency is common in patients with relapsed multiple myeloma and can often limit choice of therapy. Lenalidomide, a critical agent in the treatment of relapsed multiple myeloma, is renally cleared., This phase I/II trial evaluated the efficacy and safety of lenalidomide with dexamethasone in patients with relapsed multiple myeloma and renal insufficiency. Three groups were treated, with creatinine clearance 30-60 cc/hr (group A), CrCl < 30 not on dialysis (group B), and patients on dialysis (group C) at escalating doses of lenalidomide...
August 29, 2018: Blood Cancer Journal
https://www.readbyqxmd.com/read/30190459/biological-determinants-of-health-disparities-in-multiple-myeloma
#4
REVIEW
Cheryl Jacobs Smith, Stefan Ambs, Ola Landgren
Multiple myeloma is a rare plasma cell cancer, and incidence rates among patients of African descent are about twice those among patients of European descent. Rates of multiple myeloma vary among different populations, but the reasons for the racial disparities in multiple myeloma are largely unknown. Epidemiology has identified risk factors for multiple myeloma including race, advanced age, gender, family history, and exposure to different genetic toxins including radiation. Race and ancestry play a large role in predicting the risk for multiple myeloma, yet there exists a paucity of literature that explores the molecular contribution of race and ancestry to disease...
August 28, 2018: Blood Cancer Journal
https://www.readbyqxmd.com/read/30190511/biallelic-inactivation-of-the-retinoblastoma-gene-results-in-transformation-of-chronic-myelomonocytic-leukemia-to-a-blastic-plasmacytoid-dendritic-cell-neoplasm-shared-clonal-origins-of-two-aggressive-neoplasms
#5
LETTER
Mrinal M Patnaik, Terra Lasho, Matthew Howard, Christy Finke, Rhett L Ketterling, Aref Al-Kali, Animesh Pardanani, Nathalie Droin, Naseema Gangat, Ayalew Tefferi, Eric Solary
No abstract text is available yet for this article.
August 22, 2018: Blood Cancer Journal
https://www.readbyqxmd.com/read/30190488/dissecting-causes-for-improved-survival-among-patients-with-acute-myeloid-leukemia-in-two-different-eras-receiving-identical-regimens-in-sequential-randomized-studies
#6
LETTER
Ing S Tiong, John Reynolds, Kenneth F Bradstock, John F Seymour, Andrew H Wei
No abstract text is available yet for this article.
August 22, 2018: Blood Cancer Journal
https://www.readbyqxmd.com/read/30190479/expression-profile-of-translation-initiation-factor-eif2b5-in-diffuse-large-b-cell-lymphoma-and-its-correlation-to-clinical-outcome
#7
LETTER
Julia J Unterluggauer, Katharina Prochazka, Peter V Tomazic, Heinrich J Huber, Rita Seeboeck, Karoline Fechter, Elisabeth Steinbauer, Verena Gruber, Julia Feichtinger, Martin Pichler, Marc A Weniger, Ralf Küppers, Heinz Sill, Rudolf Schicho, Peter Neumeister, Christine Beham-Schmid, Alexander J A Deutsch, Johannes Haybaeck
No abstract text is available yet for this article.
August 22, 2018: Blood Cancer Journal
https://www.readbyqxmd.com/read/30190472/the-biological-significance-of-histone-modifiers-in-multiple-myeloma-clinical-applications
#8
Hiroto Ohguchi, Teru Hideshima, Kenneth C Anderson
Multiple myeloma (MM) is a clonal plasma cell disorder that is characterized by a variety of genetic alterations. Recent studies have highlighted not only the importance of these genetic events but also epigenetic aberrations including DNA methylation, histone modifications, and non-coding RNAs in the biology of MM. Post-translational modifications of histone, such as methylation and acetylation, contribute to chromatin dynamics, and are modulated by histone modifying enzymes, and dysregulation of these enzymes is implicated in the pathogenesis of cancers, including MM...
August 22, 2018: Blood Cancer Journal
https://www.readbyqxmd.com/read/30190468/development-of-a-novel-target-module-redirecting-unicar-t-cells-to-sialyl-tn-expressing-tumor-cells
#9
LETTER
L R Loureiro, A Feldmann, R Bergmann, S Koristka, N Berndt, C Arndt, J Pietzsch, C Novo, P Videira, M Bachmann
No abstract text is available yet for this article.
August 22, 2018: Blood Cancer Journal
https://www.readbyqxmd.com/read/30190453/survival-after-blinatumomab-treatment-in-pediatric-patients-with-relapsed-refractory-b-cell-precursor-acute-lymphoblastic-leukemia
#10
LETTER
Lia Gore, Franco Locatelli, Gerhard Zugmaier, Rupert Handgretinger, Maureen M O'Brien, Peter Bader, Deepa Bhojwani, Paul-Gerhardt Schlegel, Catherine A Tuglus, Arend von Stackelberg
No abstract text is available yet for this article.
August 22, 2018: Blood Cancer Journal
https://www.readbyqxmd.com/read/30104611/the-prognostic-significance-of-global-aberrant-alternative-splicing-in-patients-with-myelodysplastic-syndrome
#11
Yi-Tsung Yang, Yu-Chiao Chiu, Chein-Jun Kao, Hsin-An Hou, Chien-Chin Lin, Cheng-Hong Tsai, Mei-Hsuan Tseng, Wen-Chien Chou, Hwei-Fang Tien
Aberrant alternative splicing (AS) is a hallmark of cancer development. However, there are limited data regarding its clinical implications in myelodysplastic syndrome (MDS). In this study, we performed an in-depth analysis of global AS in 176 primary MDS patients with 20 normal marrow transplant donors as reference. We found that 26.9% of the expressed genes genome-wide were aberrantly spliced in MDS patients compared with normal donors. These aberrant AS genes were related to pathways involved in cell proliferation, cell adhesion and protein degradation...
August 13, 2018: Blood Cancer Journal
https://www.readbyqxmd.com/read/30097561/rbfox2-and-alternative-splicing-in-b-cell-lymphoma
#12
LETTER
Hilmar Quentmeier, Claudia Pommerenke, Stephan H Bernhart, Wilhelm G Dirks, Vivien Hauer, Steve Hoffmann, Stefan Nagel, Reiner Siebert, Cord C Uphoff, Margarete Zaborski, Hans G Drexler
No abstract text is available yet for this article.
August 10, 2018: Blood Cancer Journal
https://www.readbyqxmd.com/read/30087319/multiple-myeloma-family-history-and-mortality-in-second-primary-cancers
#13
LETTER
Subhayan Chattopadhyay, Hongyao Yu, Amit Sud, Jan Sundquist, Asta Försti, Akseli Hemminki, Kari Hemminki
No abstract text is available yet for this article.
August 7, 2018: Blood Cancer Journal
https://www.readbyqxmd.com/read/30087318/heterogeneous-prognosis-among-kit-mutation-types-in-adult-acute-myeloid-leukemia-patients-with-t-8-21
#14
LETTER
Ya-Zhen Qin, Hong-Hu Zhu, Qian Jiang, Lan-Ping Xu, Hao Jiang, Yu Wang, Xiao-Su Zhao, Yan-Rong Liu, Xiao-Hui Zhang, Kai-Yan Liu, Xiao-Jun Huang
No abstract text is available yet for this article.
August 7, 2018: Blood Cancer Journal
https://www.readbyqxmd.com/read/30069017/non-invasive-monitoring-of-diffuse-large-b-cell-lymphoma-by-cell-free-dna-high-throughput-targeted-sequencing-analysis-of-a-prospective-cohort
#15
Elodie Bohers, Pierre-Julien Viailly, Stéphanie Becker, Vinciane Marchand, Philippe Ruminy, Catherine Maingonnat, Philippe Bertrand, Pascaline Etancelin, Jean-Michel Picquenot, Vincent Camus, Anne-Lise Menard, Emilie Lemasle, Nathalie Contentin, Stéphane Leprêtre, Pascal Lenain, Aspasia Stamatoullas, Hélène Lanic, Julie Libraire, Sandrine Vaudaux, Louis-Ferdinand Pepin, Pierre Vera, Hervé Tilly, Fabrice Jardin
From a liquid biopsy, cell-free DNA (cfDNA) can provide information regarding basal tumoral genetic patterns and changes upon treatment. In a prospective cohort of 30 diffuse large B-cell lymphomas (DLBCL), we determined the clinical relevance of cfDNA using targeted next-generation sequencing and its correlation with PET scan imaging at the time of diagnosis and during treatment. Using a dedicated DLBCL panel, mutations were identified at baseline for 19 cfDNAs and profiles were consistent with expected DLBCL patterns...
August 1, 2018: Blood Cancer Journal
https://www.readbyqxmd.com/read/30069001/history-of-autoimmune-conditions-and-lymphoma-prognosis
#16
Geffen Kleinstern, Matthew J Maurer, Mark Liebow, Thomas M Habermann, Jean L Koff, Cristine Allmer, Thomas E Witzig, Grzegorz S Nowakowski, Ivana N Micallef, Patrick B Johnston, David J Inwards, Carrie A Thompson, Andrew L Feldman, Brian K Link, Christopher Flowers, Susan L Slager, James R Cerhan
Autoimmune conditions are strong risk factors for developing lymphoma, but their role in lymphoma prognosis is less clear. In a prospective cohort study, we evaluated self-reported history of eight autoimmune conditions with outcomes in 736 diffuse large B-cell, 703 follicular, 302 marginal zone (MZL), 193 mantle cell (MCL), 297 Hodgkin lymphoma (HL), and 186 T-cell lymphomas. We calculated event-free survival (EFS) and overall survival (OS), and estimated hazard ratios (HRs) and 95% confidence intervals (CIs), adjusting for sex, prognostic score, and treatment...
August 1, 2018: Blood Cancer Journal
https://www.readbyqxmd.com/read/30065290/myelofibrosis-treatment-algorithm-2018
#17
REVIEW
Ayalew Tefferi, Paola Guglielmelli, Animesh Pardanani, Alessandro M Vannucchi
Two novel prognostic systems for primary myelofibrosis (PMF) were recently unveiled: GIPSS (genetically inspired prognostic scoring system) and MIPSS70 (mutation-enhanced international prognostic scoring system for transplant-age patients). GIPSS is based exclusively on genetic markers: mutations and karyotype. MIPSS70 includes mutations and clinical risk factors. In its most recent adaptation, the prognostic value of MIPSS70 has been bolstered by the inclusion of a three-tiered cytogenetic risk stratification and use of hemoglobin thresholds that are adjusted for sex and severity (MIPSS70+ version 2...
July 31, 2018: Blood Cancer Journal
https://www.readbyqxmd.com/read/30065277/bendamustine-pomalidomide-and-dexamethasone-for-relapsed-and-or-refractory-multiple-myeloma
#18
Dharshan Sivaraj, Michael M Green, Yubin Kang, Gwynn D Long, David A Rizzieri, Zhiguo Li, Anderson H Garrett, Jackie L McIntyre, Nelson J Chao, Cristina Gasparetto
No abstract text is available yet for this article.
July 31, 2018: Blood Cancer Journal
https://www.readbyqxmd.com/read/30061664/phase-1-2-trial-of-ixazomib-cyclophosphamide-and-dexamethasone-in-patients-with-previously-untreated-symptomatic-multiple-myeloma
#19
Shaji K Kumar, Francis K Buadi, Betsy LaPlant, Alese Halvorson, Nelson Leung, Prashant Kapoor, David Dingli, Morie A Gertz, Ronald S Go, P Leif Bergsagel, Yi Lin, Angela Dispenzieri, Yi Lisa Hwa, Amie Fonder, Miriam Hobbs, Rafael Fonseca, Suzanne R Hayman, A Keith Stewart, John A Lust, Joseph Mikhael, Wilson Gonsalves, Craig Reeder, Tomas Skacel, S Vincent Rajkumar, Martha Q Lacy
Ixazomib is the first oral proteasome inhibitor to enter the clinic. Given the efficacy of bortezomib in combination with cyclophosphamide and dexamethasone, we studied the combination of ixazomib, cyclophosphamide and dexamethasone (ICd) in newly diagnosed multiple myeloma (NDMM) and patients with measurable disease, irrespective of transplant eligibility, were enrolled. The phase 1 was to determine the maximum tolerated dose (MTD) of cyclophosphamide in the combination. Patients received ixazomib 4 mg (days 1, 8, 15), dexamethasone 40 mg (days 1, 8, 15, 22), and cyclophosphamide 300 or 400 mg/m2 days 1, 8, 15, 22; cycles were 28 days...
July 30, 2018: Blood Cancer Journal
https://www.readbyqxmd.com/read/30061683/clonal-hematopoiesis-in-patients-with-rheumatoid-arthritis
#20
LETTER
Paula Savola, Sofie Lundgren, Mikko A I Keränen, Henrikki Almusa, Pekka Ellonen, Marjatta Leirisalo-Repo, Tiina Kelkka, Satu Mustjoki
No abstract text is available yet for this article.
July 26, 2018: Blood Cancer Journal
journal
journal
43747
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"